Skip to main content

Table 2 Association of incompatibility at G1m (G1m1,17- genotype) with less improvement in DAS28 at six months of treatment with anti-TNF in the discovery samples

From: Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study

      Unadjusted Adjusted b Adjusted b
  G1m genotype a number Baseline DAS28 ΔDAS28 Beta P-value Beta P-value
All patients G1m1,17+ 92 5.9 ± 1.1 2.3 ± 1.6 0.20 0.006 0.14 0.02
  G1m1,17- 94 5.7 ± 1.1 1.6 ± 1.5     
INX G1m1,17+ 68 5.9 ± 1.1 2.1 ± 1.6 0.16 0.06 0.16 0.03
  G1m1,17- 72 5.8 ± 1.1 1.6 ± 1.5     
ADM G1m1,17+ 24 6.1 ± 1.3 2.9 ± 1.5 0.32 0.03 0.16 0.19
  G1m1,17- 22 5.6 ± 1.4 1.9 ± 1.5     
  1. aCarrier status; banalyses adjusted for baseline DAS28, gender and RF (and anti-TNF for All patients). ADM, adalimumab; anti-TNF, anti-tumor necrosis factor; DAS28, disease activity score in 28 joints; INX, infliximab; RF, rheumatoid factor.
Back to article page